Barr, Organon and Savient finalise Mircette settlement

Published: 7-Dec-2005

Barr Pharmaceuticals, Organon USA, Organon (Ireland) and Savient Pharmaceuticals have reached agreement over the future of Organon's Mircette (desogestrel/ethinyl estradiol) oral contraceptive product.


Barr Pharmaceuticals, Organon USA, Organon (Ireland) and Savient Pharmaceuticals have reached agreement over the future of Organon's Mircette (desogestrel/ethinyl estradiol) oral contraceptive product.

The agreement, under which Barr and its subsidiaries acquire the exclusive rights to Mircette, terminates the ongoing patent litigation regarding Barr's generic version of the product, which the company markets under the trade name Kariva.

Barr's Duramed Pharmaceuticals subsidiary will promote Mircette to female healthcare practitioners utilising its recently expanded specialty sales force.

  

You may also like